Glycomine initiates Phase 2 trial of GLM101 for PMM2-CDG
Glycomine, Inc. is conducting Phase 2 trial to evaluate GLM101 in PMM2-CDG patients, comparing it to placebo over 48 weeks.
Therapeutic Area
Therapeutic area intelligence for PMM2-CDG with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.